Recent posts

TypePostAuthorRepliesLast updated
Blog entryNovartis complaints over public interest declaration debunked Andrew Goldman049 weeks 1 day ago
Blog entryWIPO IGC30: Questions remain on protection of genetic resources as hard decisions postponed until 2017 Staff049 weeks 1 day ago
Blog entryWHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO's work on R&D thiru049 weeks 1 day ago
Book pagePrizes to stimulate innovation James Love049 weeks 2 days ago
Blog entryObama administration blocking consensus at Human Rights Council on access to medicines resolution thiru049 weeks 3 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc. Diane Singhroy049 weeks 5 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC Diane Singhroy049 weeks 5 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation Diane Singhroy049 weeks 5 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc. Diane Singhroy049 weeks 5 days ago
Blog entryAlfred Engelberg and Aaron Kesselheim in Nature on Bayh-Dole royalty free rights in patents, Xtandi case James Love049 weeks 6 days ago
Blog entryColombia Ministry of Health Announces that Negotiations With Novartis Have Failed; Declaration of Public Interest Imminent Andrew Goldman049 weeks 6 days ago
Blog entryXtandi patient on Medicare — with supplement — pays $441.97 per month Zack Struver050 weeks 28 min ago
Blog entryUS proposal to seek a "better understanding" of Switzerland's implementation of the Nagoya Protocol receives chilly reception thiru050 weeks 1 day ago
Blog entryWIPO IGC30: Narrowing existing gaps relating to the protection of genetic resources? Staff050 weeks 2 days ago
Blog entryWIPO IGC30: Clean and track-changed version of Facilitators' text on Intellectual Property and Genetic Resources thiru050 weeks 2 days ago
PageWIPO IGC30 thiru050 weeks 2 days ago
Blog entry28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug Zack Struver051 weeks 1 day ago
Blog entryHAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement KEI Staff051 weeks 2 days ago
Blog entryHAI/KEI intervention at the WHA69 on the Framework of Engagement with Non-State Actors thiru051 weeks 2 days ago
Blog entrySens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug Andrew Goldman051 weeks 5 days ago
Blog entryLetter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License James Love051 weeks 5 days ago
Blog entryHarvard's Oct. 23, 2015 forum on "Drug Pricing: Public Health Implications" Zack Struver051 weeks 6 days ago
PageColombia James Love051 weeks 6 days ago
Blog entrySenator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib Andrew Goldman051 weeks 6 days ago
Blog entry15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia Andrew Goldman051 weeks 6 days ago